Histology Division, Basic Science Department, Faculty of physical therapy, Nahda University, Beni-Suef, Egypt.
Cell Biology, Histology and Genetics Division, Department of Zoology, Faculty of Science, Beni-Suef University, Salah Salem St, P.O. Box 62521, Beni-Suef, Egypt.
Environ Sci Pollut Res Int. 2023 Apr;30(18):53589-53604. doi: 10.1007/s11356-023-26103-4. Epub 2023 Mar 2.
The aim of this study was to evaluate the anti-inflammatory, antioxidant, and antiproliferative effects of hesperidin (HSP) and eltroxin (ELT) on hypothyroidism (HPO) induced by carbimazole (CBZ) in white male albino rats. Thirty-two adult rats were categorized into four groups: Group 1, no treatment (control); Group II, treated with CBZ (20 mg/kg); Group III, treated with HSP (200 mg/kg) + CBZ; and Group IV, treated with ELT (0.045 mg/kg) + CBZ. All treatments were provided as oral daily doses for 90 days. Thyroid hypofunction was significantly manifested in Group II. However, increased levels of thyroid hormones, antioxidant enzymes, nuclear factor erythroid 2-related factor 2, heme oxygenase 1, and interleukin (IL)-10, and a decrease in the level of the thyroid-stimulating hormone were observed in Groups III and IV. On the contrary, decreased levels of lipid peroxidation, inducible nitric oxide synthase, tumor necrosis factor α, IL-17, and cyclooxygenase 2 were detected in groups III and IV. The histopathological and ultrastructural findings were ameliorated in Groups III and IV; on the contrary, Group II presented with significant increases in the height and number of layers of the follicular cells. Immunohistochemistry demonstrated a marked increase in thyroglobulin and significant decreases in the levels of nuclear factor kappa B and proliferating cell nuclear antigen in Groups III and IV. These results confirmed the effectiveness of HSP as an anti-inflammatory, antioxidant, and antiproliferative agent in rats with hypothyroidism. Additional studies are required to assess its potential as a novel agent against HPO.
本研究旨在评估橙皮苷（HSP）和依替碘（ELT）对甲状腺功能减退症（HPO）的抗炎、抗氧化和抗增殖作用，该疾病由卡比马唑（CBZ）引起，在雄性白化大鼠中诱导。将 32 只成年大鼠分为四组：第 1 组，无治疗（对照）；第 2 组，用 CBZ（20mg/kg）治疗；第 3 组，用 HSP（200mg/kg）+CBZ 治疗；第 4 组，用 ELT（0.045mg/kg）+CBZ 治疗。所有治疗均为每日口服剂量，共 90 天。第 2 组甲状腺功能减退症表现明显。然而，第 3 组和第 4 组观察到甲状腺激素、抗氧化酶、核因子红细胞 2 相关因子 2、血红素加氧酶 1 和白细胞介素（IL）-10 水平升高，促甲状腺激素水平降低。相反，第 3 组和第 4 组检测到脂质过氧化、诱导型一氧化氮合酶、肿瘤坏死因子 α、IL-17 和环氧化酶 2 水平降低。第 3 组和第 4 组的组织病理学和超微结构发现得到改善；相反，第 2 组滤泡细胞的高度和层数明显增加。免疫组织化学显示，第 3 组和第 4 组甲状腺球蛋白明显增加，核因子 kappa B 和增殖细胞核抗原水平显著降低。这些结果证实了 HSP 作为一种抗甲状腺功能减退症大鼠的抗炎、抗氧化和抗增殖剂的有效性。需要进一步的研究来评估其作为治疗 HPO 的新型药物的潜力。
